Author:
Vo Hoa Thi My,Upasani Vinit,Auerswald Heidi,Lay Sokchea,Sann Sotheary,Vanderlinden Axelle,Ken Sreymom,Sorn Sopheak,Ly Sowath,Duong Veasna,Dussart Philippe,Cantaert Tineke
Abstract
AbstractHeterotypic secondary dengue virus (DENV) infection is a risk factor for the development of severe disease. To assess the contribution of the developing polyclonal humoral immune response to the course of acute infection, we have determined anti-DENV IgG titers, neutralizing antibodies, percentages of antibodies binding to DENV-infected cells and antibody‑dependent enhancement (ADE) to the infecting serotype in DENV-infected Cambodian children (n = 58), ranging from asymptomatic dengue to severe disease. The results showed that ADE titers are highest against the infecting serotype during heterotypic secondary DENV-2 infection. Moreover, IgG titers, neutralizing antibodies and ADE titers against the infecting serotype peak at D10 and are maintained until D60 after laboratory-confirmed secondary DENV infection. Anti-DENV IgG titers and the magnitude of the functional antibody response were higher in secondary DENV-infected patients compared to primary infected patients. No differences in antibody titers, neutralizing or enhancing antibodies could be observed between asymptomatic or hospitalized patients between 6 and 8 days after laboratory-confirmed DENV-1 infection. However, at this time point, the level of IgG bound to DENV-infected cells was associated with disease severity in hospitalized patients. Taken together, our data offer insights for more comprehensive interpretation of antibody response profile to natural infection and its correlation to disease outcome.
Funder
The Pasteur Network
HHMI-Wellcome Trust
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. Gubler, D. J. The economic burden of dengue. Am. J. Trop. Med. Hyg. 86, 743–744 (2012).
2. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504–507 (2013).
3. Katzelnick, L. C. et al. Dengue viruses cluster antigenically but not as discrete serotypes. Science 349, 1338–1343 (2015).
4. Anon Srikiatkhachorn, I.-K.Y. Immune correlates for dengue vaccine development. Expert Rev. Vaccines. 176, 139–148 (2016).
5. Katzelnick, L. C. & Harris, E. Immune correlates of protection for dengue. Vaccine 176, 4659–4669 (2017).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献